Skip to main content
. 2021 May 22;35(12):3573–3577. doi: 10.1038/s41375-021-01300-7

Fig. 1. Representative T cell and antibody responses.

Fig. 1

a Post-vaccine polyfunctional CD4+ T cell response in MF patient on ruxolitinib showing TNFα and IL-2 expression in unstimulated cells (left) and cells exposed to S protein (right). b Post-vaccine polyfunctional CD8+ T cell response in MF patient on ruxolitinib showing TNFα and IFNγ expression in unstimulated cells (left) and cells exposed to S protein (right). c IgG EC50 in MF patients compared with other diagnoses. d Neutralising antibody ID50 in MF patients compared with other diagnoses.